- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03005418
Humacyte Human Acellular Vessel (HAV) in Patients With Vascular Trauma
A Phase 2/3 Study for the Evaluation of Safety and Efficacy of Humacyte's Human Acellular Vessel for Vascular Replacement or Reconstruction in Patients With Life or Limb-threatening Vascular Trauma
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a prospective, multicenter, multi cohort, non-randomized phase 2 study in up to 40 adult patients with life or limb threatening vascular trauma which requires surgical repair. There will be a limb cohort and a torso cohort. The limb cohort will include patients who require repair of a vessel contained to the upper or lower extremity. The torso cohort includes patients who require repair of vessels within the thorax (excluding the heart), abdomen, and retroperitoneum. Subjects will be implanted with a Humacyte Human Acellular Vessel (HAV) as an interposition vessel or bypass using standard vascular surgical techniques. There is no control arm.
The active study duration for each study participant will be 36 months from HAV implantation or until HAV failure/ removal/ death if earlier. Follow up after month 12 will involve the capture of information on assessments performed at "standard of care" routine clinic visits or by telephone follow up with the patient or his/her physician with physical exam and ultrasound at month 24 and month 36
The total expected duration of the clinical study is 61 months (24 months of enrollment and 36 months of follow up).
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Contact
- Name: Elizabeth Taylor
- Phone Number: 185 919-313-9633
- Email: etaylor@humacyte.com
Study Contact Backup
- Name: Mark Tulchinskiy, MD
- Phone Number: 919-313-9633
- Email: mtulchinskiy@humacyte.com
Study Locations
-
-
-
Be'er Sheva, Israel, 8410101
- Soroka Medical Center - Vascular Surgery Department
-
Haifa, Israel, 3109601
- Rambam Health Care Campus - Vascular Surgery Department
-
Jerusalem, Israel, 9103102
- Shaare Zedek Medical Center
-
Ramat Gan, Israel, 5265601
- The Chaim Sheba Medical Center - Vascular Surgery Department
-
-
-
-
California
-
La Jolla, California, United States, 92037
- Jacob Medical Center at UC San Diego
-
Los Angeles, California, United States, 90033
- Keck Hospital of University of Southern California (USC)
-
Los Angeles, California, United States, 90048
- Cedars-Sinai Medical Cener
-
Orange, California, United States, 92868
- UCI Medical Center
-
Sacramento, California, United States, 95817
- University California, Davis
-
San Diego, California, United States, 92103
- University of California San Diego (UCSD) Medical Center
-
-
Colorado
-
Denver, Colorado, United States, 80204
- Ernest E Moore Shock Trauma Center at Denver Health
-
-
Florida
-
Jacksonville, Florida, United States, 32209
- Uf Health Jacksonville
-
Miami, Florida, United States, 33136
- Ryder Trauma Center
-
Miami, Florida, United States, 33136
- Jackson South Medical Center
-
Tampa, Florida, United States, 33606
- Tampa General Hospital
-
-
Georgia
-
Atlanta, Georgia, United States, 30303
- Grady Memorial Hospital
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
- Johns Hopkins Hospital
-
Baltimore, Maryland, United States, 21224
- Johns Hopkins Bayview Medical Center
-
Baltimore, Maryland, United States, 21201
- R Adams Cowley Baltimore Shock Trauma
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Saint Louis University (SLU)
-
-
New Jersey
-
Camden, New Jersey, United States, 08103
- Cooper University Hospital
-
Newark, New Jersey, United States, 07103
- Rutgers New Jersey Medical School
-
-
North Carolina
-
Durham, North Carolina, United States, 27705
- Duke University Hospital
-
Winston-Salem, North Carolina, United States, 27157
- Wake Forest School of Medicine
-
Winston-Salem, North Carolina, United States, 27157
- Atrium Health Wake Forest Baptist Medical Center
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Oregon Health & Science University
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19140
- Temple University Hospital
-
Philadelphia, Pennsylvania, United States, 19104
- Penn Presbyterian Medical Center
-
-
Tennessee
-
Nashville, Tennessee, United States, 37232
- Vanderbilt University Medical Center
-
-
Texas
-
Austin, Texas, United States, 78701
- The University of Texas - Dell Medical School
-
-
Virginia
-
Charlottesville, Virginia, United States, 22908
- University of Virginia Health System
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients with life or limb threatening traumatic injury to an arterial vessel in the limb or torso, other than the heart, which requires replacement or reconstruction
- Preoperative imaging or clinical examination indicates the damaged vessel has a defect length of ≤ 38cm and is appropriately size matched to the 6mm Human Acellular Vessel (HAV) per the judgment of the treating surgeon taking into account vasoconstriction and situational inflow and outflow considerations.
- Autologous vein graft is either not feasible in the judgment of the treating surgeon (e.g. because of lack of availability of suitable conduit, presence of severe venous insufficiency) or is not desirable because of the urgency of revascularization
- Aged 18 to 85 years old, inclusive
- Able to communicate meaningfully with investigative staff, and able to comply with entire study procedures. If the patient is unconscious, then information from a reliable witness indicates that the patient would normally be able to comply with study procedures
- Patient or relative is able, willing and competent to give informed consent
- Life expectancy of at least 1 year
Exclusion Criteria:
- Mangled Extremity Severity Score (MESS) of ≥ 7
- Limb at high risk of amputation despite vascular reconstruction (e.g., because of crush injury)
- Catastrophic injuries that make survival unlikely (e.g. Abbreviated Injury Scale (AIS) > 5 or Injury Severity Score (ISS) >60)
- HAV may not be used for coronary artery repair
- Known pregnant women
- Known medical condition which would preclude long term antiplatelet therapy after resolution of acute injuries
- Any other condition which in the judgment of the investigator would preclude adequate evaluation of the safety and efficacy of the HAV
- Previous exposure to HAV
- Known participation in any investigational study within the last 30 days
- Employees of the sponsor or patients who are employees or relatives of the investigator
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Human Acellular Vessel (HAV)
Patients with life or limb threatening traumatic injury to an arterial vessel in the limb or torso, other than the heart, will be implanted with the Humacyte Human Acellular Vessel (HAV) as an interposition vessel or bypass using standard vascular surgical techniques.
|
The investigational medicinal product (IMP) - the Human Acellular Vessel (HAV) is a sterile acellular tubular graft composed of human collagen types I and III and other extracellular matrix proteins, including fibronectin and vitronectin which can be used for arterial bypass or reconstruction in patients with life or limb threatening vascular trauma.
The vessel is 6 mm in diameter and approximately 42 cm in length.
The product is supplied on a silicone mandrel immersed in sterile phosphate buffered saline in a sealed and labeled plastic container.
The Humacyte HAV is implanted using standard vascular surgical techniques similar to placement of predicate peripheral vascular prostheses.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
HAV primary patency
Time Frame: 30 days
|
Primary patency is defined as 'the interval from the time of access placement until any intervention designed to maintain or reestablish patency, access thrombosis or the measurement of patency', i.e., patent without interventions
|
30 days
|
Frequency and Severity of Adverse Events
Time Frame: 36 months
|
36 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Patient survival
Time Frame: 36 months
|
36 months
|
|
Limb viability (avoidance of amputation; limb cohort only)
Time Frame: 36 months
|
36 months
|
|
HAV primary patency
Time Frame: 36 months
|
Primary patency is defined as 'the interval from the time of access placement until any intervention designed to maintain or reestablish patency, access thrombosis or the measurement of patency', i.e., patent without interventions
|
36 months
|
HAV primary assisted patency
Time Frame: 36 months
|
Primary assisted patency is defined as 'the interval from the time of access placement until access thrombosis or the time of measurement of patency, including intervening manipulations (surgical or endovascular interventions) designed to maintain the functionality of patent access' i.e., patent without an intervention to clear a thrombus
|
36 months
|
HAV secondary patency
Time Frame: 36 months
|
Secondary patency is defined as 'the interval from the time of access placement until access abandonment', i.e., patent with or without interventions
|
36 months
|
Rate of HAV interventions
Time Frame: 36 months
|
36 months
|
|
HAV remodeling as shown by histopathology of any clinical explants
Time Frame: 36 months
|
36 months
|
|
Frequency of anastomotic bleeding or spontaneous rupture
Time Frame: 36 months
|
36 months
|
|
Frequency of HAV infection
Time Frame: 36 months
|
36 months
|
|
Frequency of HAV thrombosis
Time Frame: 36 months
|
36 months
|
|
Frequency of HAV pseudoaneursym formation
Time Frame: 36 months
|
36 months
|
|
Frequency of HAV aneursym formation
Time Frame: 36 months
|
36 months
|
|
Frequency of HAV of hemodynamically significant stenosis (>70% by duplex ultrasound criteria)
Time Frame: 36 months
|
36 months
|
|
Frequency of HAV removal
Time Frame: 36 months
|
36 months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Shamik Parikh, MD, Humacyte, Inc.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CLN-PRO-V005
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Trauma
-
Humacyte, Inc.Active, not recruitingTrauma | Trauma Injury | Trauma, Multiple | Trauma BluntUkraine
-
Wonju Severance Christian HospitalNational Research Foundation of KoreaRecruitingTrauma Injury | Trauma, MultipleKorea, Republic of
-
Prof. Dr. Cemil Tascıoglu Education and Research...CompletedTrauma Injury | Trauma, MultipleTurkey
-
University Hospital, AngersRecruiting
-
Rabin Medical CenterIsraeli Ministry of SecurityUnknown
-
Oslo University HospitalUniversity of Oslo; Sunnaas Rehabilitation Hospital; South-Eastern Norway Regional...RecruitingTrauma Injury | Trauma, Multiple | PolytraumaNorway
-
Chang, Steve S., M.D.Santa Barbara Cottage Hospital; Accumetrics, Inc.CompletedHead Injury Trauma BluntUnited States
-
Assistance Publique - Hôpitaux de ParisFrancophone Pediatric Resuscitation and Emergency Group (GFRUP)Completed
-
Norwegian University of Science and TechnologySt. Olavs HospitalTerminatedTrauma, Multiple | Trauma Severity Indices | Injuries, Multiple | Norway/Epidemiology | Trauma Centers/Statistics & Numerical Data
-
University Hospital, ToulouseNot yet recruiting
Clinical Trials on Human Acellular Vessel (HAV)
-
Humacyte, Inc.Atlantic Research GroupCompletedPeripheral Artery DiseaseUnited States
-
Humacyte, Inc.AvailableVascular Diseases | End Stage Renal Disease on Dialysis | Vascular System Injuries
-
Humacyte, Inc.FGK Clinical Research GmbHActive, not recruitingPeripheral Arterial Disease | Peripheral Vascular DiseasePoland
-
Humacyte, Inc.California Institute for Regenerative Medicine (CIRM); CTI Clinical Trial and...Active, not recruitingRenal Failure | Hemodialysis | End Stage Renal Disease | Vascular AccessUnited States
-
Humacyte, Inc.California Institute for Regenerative Medicine (CIRM); CTI Clinical Trial and...CompletedRenal Failure | Hemodialysis | End Stage Renal Disease | Vascular AccessUnited States, Israel, United Kingdom, Portugal, Poland, Germany
-
Henry Ford Health SystemCompleted
-
Musculoskeletal Transplant FoundationWashington University School of Medicine; Pines Surgical; Meridian Healthcare...CompletedHernia of Abdominal WallUnited States
-
Humacyte, Inc.FGK Clinical Research GmbHActive, not recruitingKidney Failure, Chronic | End-stage Renal DiseasePoland
-
SGM Physician Research ConsortiumMusculoskeletal Transplant FoundationCompletedLower Eyelid RetractionUnited States
-
Zimmer BiometZimmer DentalCompletedGingival RecessionUnited States